Articles On Recce Pharmaceuticals (ASX:RCE)

Sydney-based anti-infective company Recce Pharmaceuticals (ASX:RCE) has announced an Antiviral SARS-CoV-2 Screening Program Agreement with CSIRO and the University of Melbourne's Doherty...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is on watch today after the company announced it has entered into an antiviral Sars-CoV-2 screening program. Recce (pronounced ‘recky’) is pioneering a new class of synthetic antibiotics...

Recce Pharmaceuticals (RCE) Executive Director Michele Dilizia joins Peter Switzer.

Backpackers in Bondi were pilloried for spreading COVID-19, but everyone knows gonorrhoea is a greater risk in the suburb’s sandy stews. Antibiotic maker Recce Pharmaceuticals (ASX: RCE) says its lead candidate is proving to be effective ag...

COVID-19 may seem the only bug worth seeking to squash right now but there are at least two other battles that haven’t witnessed a ceasefire. One prominant group of bugs are the so-called “super bugs” — bacteria which as its name suggests c...

A study into a new class of synthetic antibiotics developed by Recce Pharmaceuticals (ASX: RCE) has produced positive data showing significant in vivo anti-viral activity against Influenza A virus in mice being treated with the company’s pa...

While we need all the bacteria fighters we can get right now, they are not immune to the coronovirus panic and Next Science (ASX:NXS) is the latest to admit it hasn’t been able to escape the impact. The company, which listed last April and...

Sydney-based Recce Pharmaceuticals (ASX:RCE), a company developing a new class of broad-spectrum synthetic antibiotics, has updated on progress to begin the first human trials of its lead compound RECCE 327.

Recce Pharmaceuticals (RCE) has announced positive data from its RECCE 327 antibiotic study on rats and dogs RECCE 327 is addressing the increasing threat of superbugs that are resistant to antibiotics Studies indicated that various dosage...

Since mid-October Zoono (ASX:ZNO) has climbed from 8.2c to $1.20 this morning — a 1,382 per cent spike. And it is still climbing after more good news this morning. The antimicrobial solution maker unveiled its latest distribution agreement...

With triple the number of sepsis cases in Australia, small cap biotech company Cynata Therapeutics (ASX:CYP) hopes to wage a new war on blood infections. Last Friday the world learned blood infections were on the rise, with researchers show...

Also presenting at the CEO Sessions will be Great Boulder Resources, Recce Pharmaceuticals and Antisense Therapeutics.

Five companies will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.

Every week Stockhead publishes a weekly column of directors trades of $100,000 or more among ASX small caps. As 2019 draws to a close, we thought we could re-cap the most noteworthy trades.   Biggest trade Wagners (ASX:WGN) co-founders Deni...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Race Oncology (ASX:RCE) CEO Peter Mol...

Industrial Sector or the secondary sector of the economy processes raw materials / inputs provided by other sectors into manufactured goods and finished products. Some economists are of the view that manufacturing industry generates more we...

In the Australian health care system, three levels of government are responsible for providing universal health care- federal government, state and territory government and local government. Funding and indirect support are provided by the...

For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he...

E-sports, technology, biotech and primary producer stocks are all experiencing growing interest from Asian investors. This partially reflects rising investor sophistication, as well as the chance to pursue Australian investments in sectors...

On Stockhead today: five water treatment stocks surge 260 per cent in a year, the ASX’s most intriguing bargain barrel stocks, the five 2019 IPO stocks delivering triple returns and Dorado-3 oil flow gets Carnarvon on track. But first:   Th...

Synthetic antibiotics developer Recce Pharmaceuticals has tasked Shaw and Partners with raising fresh funds for the company on Tuesday. 

Shaw and Partners has been appointed as Lead Manager to an equity capital raising by Recce Pharmaceuticals Limited (RCE).   RCE is undertaking a placement of approx. 15.5... Read More

Publicly traded companies lay great emphasis on their respective share price, which mirrors their overall financial health. Analysts, media houses and industry experts vigilantly gauge at the stocks riding high on stock exchanges. Typically...

The company is pioneering the development of a new class of synthetic antibiotics with broad-spectrum activity, designed to address the problem of antibiotic superbugs.

This week only six directors traded $100,000 or more. So we’ve also recapped some big directors’ trades from earlier this year seeing if they paid off – including that millennial director who spent $100,000 on his company rather than a hous...

Pot stock Botanix (ASX:BOT) says one of its cannabis formulations kills superbugs — in animals and in the lab. Botanix is better known to investors as a biotech developing cannabis-based medications for skin conditions, but it also has a re...